# EQRx

> EQRx launched in 2020 to develop lower-cost branded medicines but wound down programs after a 2023 acquisition by Revolution Medicines.

## Why it is interesting

Alexis Borisy’s “fast follower” pricing thesis raised $2B+ in venture and SPAC capital before FDA setbacks forced a strategic reset — a cautionary tale in biotech capital efficiency.

## Profile

- **Stage:** acquired
- **Status:** acquired
- **Industries:** generalist-tech
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Series A (Jan 2020): $200M co-led by ARCH Venture Partners, GV, and a16z (Businesswire)
- Exit (Nov 2023): Acquired by Revolution Medicines; EQRx wound down R&D programs (BioPharma Dive)

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz
- https://venturecapitaltracker.com/fund/arch-venture-partners

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/eqrx